Beta společnosti Aerie Pharmaceuticals Inc
Jaká je hodnota metriky Beta společnosti Aerie Pharmaceuticals Inc?
Hodnota metriky Beta společnosti Aerie Pharmaceuticals Inc je 0.00
Jaká je definice metriky Beta?
BETA koeficient vyjadřuje, zda je akcie více či méně volatilní než trh jako celek. Beta menší než 1 znamená, že akcie jsou méně volatilní než trh, zatímco beta větší než 1 znamená, že akcie jsou volatilnější. Volatilita se měří pomocí fluktuace ceny akcie.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Beta společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Aerie Pharmaceuticals Inc
Čemu se věnuje společnost Aerie Pharmaceuticals Inc?
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Firmy s metrikou beta podobnou společnosti Aerie Pharmaceuticals Inc
- Hodnota metriky Beta společnosti Vision Marine Technologies je 0.00
- Hodnota metriky Beta společnosti Ely Gold Royalties je 0.00
- Hodnota metriky Beta společnosti Glacier Lake Resources je 0.00
- Hodnota metriky Beta společnosti Magnum Mining and Exploration je 0.00
- Hodnota metriky Beta společnosti Africa Opportunity Fund je 0.00
- Hodnota metriky Beta společnosti Fulcrum Utility Services je 0.00
- Hodnota metriky Beta společnosti Aerie Pharmaceuticals Inc je 0.00
- Hodnota metriky Beta společnosti Gullewa je 0.00
- Hodnota metriky Beta společnosti S.A.L. Steel je 0.00
- Hodnota metriky Beta společnosti Andina Acquisition III je 0.00
- Hodnota metriky Beta společnosti Andina Acquisition III je 0.00
- Hodnota metriky Beta společnosti Brilliant Acquisition je 0.00
- Hodnota metriky Beta společnosti Indokem je 0.00